Dr Rob Clemmitt is Head of Cell & Gene Therapy (CGT) Medicine & Process Delivery (MPD) in Platform Technology & Sciences (PTS, CMC) in R&D at GlaxoSmithKline. In this role he leads the leaders responsible for the global CGT projects from candidate selection, through first time in humans, P3 and into commercial treatment. He is a core member of the CGT platform leadership team, the CGT matrix governance and delivery processes and a key partner to the Therapy Areas and other internal and external contributors to the modality. He is also a core member of the MPD leadership team, supporting matrix leadership across all of our small molecule, biopharm and CGT development projects. Previously he has held roles of increasing responsibility in biopharm MPD, most notably leading the P3 development, registration and launch of NUCALA (mepolizumab, an aIL-5), a first in class for eosinophilic asthma, in the US, EU and Japan. Significantly, in parallel, he also led the global R&D development for the follow on NUCALA liquid combination product and led the autologous, ex-vivo, haematopoietic stem cell CGT projects for Metachromatic LeukoDystrophy (MLD) and Wiskott Aldrich Syndrome (WAS). Before that, he worked in technical roles in Global Manufacturing & Supply (GMS) supporting P3/file/launch for late stage and lifecycle assets. Earlier, he worked in process development at Bio Products Laboratory and as a post-doctoral researcher (specialising in novel protein and cell separation technologies) at the University of Cambridge.

Rob has 18years experience of the development, manufacturing and commercialisation of biologicals, including all phases from candidate selection to post-launch. These have included 7years CMC matrix leadership experience. He holds a PhD, an MA and a BA in Bio Chemical Engineering from Cambridge University. Rob is dedicated to the development of innovative therapies, the development of leaders and teams and striving for excellence.